In a 12-week randomized, placebo-controlled trial, 18 g daily of Himalayan Tartary buckwheat sprout powder, rich in the flavonoid rutin, did not change the primary outcome, PROMIS Cognitive Function, among 662 analyzed adults with self-reported cognitive difficulties (contrast 0.03, 95% CI -0.07 to 0.13). Perceived Cognitive Abilities improved slightly faster with buckwheat (p = .046), a result that did not survive Bonferroni correction. Exploratory computerized testing showed faster Flanker and Stroop reaction times without lost accuracy. Side effects matched placebo.
The headline result is a miss, and the encouraging signals deserve skepticism. A nominal p-value of .046 across multiple outcomes is the textbook profile of a chance finding. The 68.7% versus 52.5% responder comparison rests on only 296 participants with final-week data, out of 848 randomized, so differential dropout could distort it. That large placebo response also shows how much expectation shapes self-rated cognition. Reaction-time gains were exploratory, and the epigenetic age findings (n = 34) cannot support any conclusion. Flavonoid-rich foods such as berries and cocoa have shown modest cognitive benefits in earlier trials, but effects on subjective measures have been inconsistent, and nothing here links buckwheat sprouts to dementia risk or longevity. This is a preprint and has not been peer reviewed, so the analysis and conclusions may change. Editorially, this is an incremental, hypothesis-generating result. Adults seeking cognitive protection are better served by exercise, sleep, blood pressure control and a flavonoid-rich diet than by this specific powder.
